Alois Gratwohl


Affiliation: University Hospital
Country: Switzerland


  1. request reprint
    Gratwohl A, Baldomero H, Labar B, Apperley J, Urbano Ispizua A. Evolution of hematopoietic stem cell transplantation in Eastern and Western Europe from 1990 to 2003. A report from the EBMT activity survey. Croat Med J. 2004;45:689-94 pubmed
    ..Another important factor seems to be the access to the therapeutic procedure. These data provide a basis for health care planning. ..
  2. request reprint
    Gratwohl A, Baldomero H, Schwendener A, Gratwohl M, Apperley J, Niederwieser D, et al. Predictability of hematopoietic stem cell transplantation rates. Haematologica. 2007;92:1679-86 pubmed
    ..They are primarily influenced by GNI per capita. The absence of saturation and a nearly linear trend indicate that infrastructure lags behind medical needs. Isolated changes in single disease entities can easily be recognized. ..
  3. Gratwohl A, Baldomero H, Aljurf M, Pasquini M, Bouzas L, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303:1617-24 pubmed publisher
    ..Hematopoietic stem cell transplantation is used for a broad spectrum of indications worldwide, but most frequently in countries with higher gross national incomes, higher governmental health care expenditures, and higher team densities. ..
  4. request reprint
    Gratwohl A. Risk assessment in haematopoietic stem cell transplantation. Best Pract Res Clin Haematol. 2007;20:119-24 pubmed
  5. Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer. 2009;115:4715-26 pubmed publisher
    ..Five well-defined pretransplant patient and donor characteristics give a reasonable risk estimate of allogeneic HSCT. This risk score can provide a basis for the decision between transplant and nontransplant strategies. ..
  6. Gratwohl A, Baldomero H. European survey on clinical use of cord blood for hematopoietic and non-hematopoietic indications. Transfus Apher Sci. 2010;42:265-75 pubmed publisher
    ..3 (range 0.1-234.6) and a proportion of CB amongst allogeneic HSCT from 0.7% to 18.2% (median 5.4%). These data document the established role of CB HSCT in Europe but point to significant differences in its use. ..